financial results

The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.

The lawsuits allege the company made false and/or misleading statement and/or failed to disclose information that was pertinent to investors.

The Salt Lake City-based molecular diagnostics company completed a $7.1 million initial public offering on the Nasdaq in July.

The company attributed the revenue decline to ongoing changes in how it bills for its diagnostics.

The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.

The company's net loss climbed about 30 percent to $4.0 million for Q4 2017, and reached $19.4 million for the full year.

The company saw a drop in its Q4 sample accessions compared to the same quarter last year, but posted increases in both testing and revenues for the full year.

The company attributed the decline in part to fewer orders for its Epi proColon colorectal cancer test.

The company's revenues were primarily driven by its various collaborations, which include ones with Qiagen and Merck KGaA.

The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.